The LICR Board of Directors has appointed Benoît Van den Eynde, M.D., Ph.D., Director-Designate of the LICR Brussels Branch.

Dr. Thierry Boon, the Founding Director of the Branch, announced last year that he wouldstep down as director at the end of the year 2009.
The Board's appointment of Dr. Van den Eynde was made following external review and a recommendation from the Scientific Director and the President. More...

Research paper published in Volume 28 of Immunity by Demotte N and van der Bruggen P made the cover of the March 2008 issue of Immunity.

The paper called "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes." can be accessed from the Immunity web site More...

The prize, awarded under the auspices of the two Royal Academies of Belgium, is one
of the most important ones granted by a private corporation. Dr. Van den
Eynde receives the Francophone prize for the period 2004-2006 for his group's
discovery of a brand new mechanism for processing of antigenic peptides.
More...

Thierry Boon Falleur a été élu, depuis le 1er mai, membre effectif de la très prestigieuse National Academy of Sciences (NAS) des Etats-Unis.
Même si la vénérable institution, créée en 1863 par le président Lincoln, compte quelques 2300 membres dont 350 étrangers, on n'entre pas là comme dans un moulin. More...

LICR and GlaxoSmithKline (GSK), the world's second-largest pharmaceutical company, have announced the signing of an agreement whereby GSK has licensed a substantial portfolio of tumor-specific antigens from LICR.
This licensing agreement follows a long-standing collaboration between both parties - specifically with the team led by Dr. Thierry Boon (Director, Brussels Branch). More...

Dr. Thierry Boon, Director of the Branch, has been elected as a Foreign Associate of the National Academy of Sciences USA. More...

Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with metastatic melanoma, the great promise of cancer vaccines - controlling tumor growth and cancer spread without serious side-effects - remains as yet unrealized. This could be set to change with the publication of a new mouse model technology from a multi-national team led by investigators at the Brussels Branch of the international Ludwig Institute for Cancer Research (LICR). More...